Wednesday, December 11, 2019 1:39:02 PM
Back to News Results
Sienna Biopharmaceuticals Will Be Delisted from Nasdaq -- Market Talk
11:57 am ET December 11, 2019 (Dow Jones) Print
1157 ET - Sienna Biopharmaceuticals has requested that Nasdaq delist the company's stock as of Friday. The clinical-stage biopharmaceutical company, which went public in 2017 and filed for chapter 11 bankruptcy protection in September, said Tuesday it will shut down by the end of the week. Sienna's stock was to remain conditionally listed on the Nasdaq pending the results of a sale process, which resulted in Sienna receiving approval to sell one of its topical medications to Sebacia Inc, a commercial-stage dermatology and aesthetics company, for about $1.7M. The company did not receive bids for any of its other assets. (aisha.al-muslim@wsj.com; @aishaalmuslim)
(END) Dow Jones Newswires
December 11, 2019 11:57 ET (16:57 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM